The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.

At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.

Eli Lilly and Company has entered into a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide, worldwide ...

J&J’s Rybrevant and cancer vaccines are showing benefit, with detailed data presented at ASCO. Credit: Hindi Studio / Shutterstock.com During the American Society of Clinical Oncology (ASCO) meeting ...

AstraZeneca has secured FDA approval for Imfinzi in combination with BCG induction and maintenance therapy for adults with BCG-naïve, high-risk NMIBC.

Several companies have presented compelling data from multiple myeloma studies at the 2026 American Society of Clinical Oncology (ASCO) meeting. Data was announced by both Bristol Myers Squibb (BMS) ...

Since Brinsupri’s approval, Insmed has been at the forefront of non-cystic fibrosis bronchiectasis (NCFB), supporting programs to increase disease awareness and to improve clinical outcomes in this ...

Japan’s pharmaceutical sector is gradually reorienting from deep, validation-led development towards execution-driven partnerships, as global pressure compresses timelines across drug development.

Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.

AbbVie’s ultra-rare blood cancer ADC secured FDA clearance while AstraZeneca’s oral SERD for breast cancer remains in regulatory limbo.

Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical pipeline.

AstraZeneca and Daiichi Sankyo have secured approval from the US FDA for Datroway (datopotamab deruxtecan) to treat metastatic TNBC.